These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 21935949

  • 41. Recent Advances in Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions.
    Ricarte RG, Van Zee NJ, Li Z, Johnson LM, Lodge TP, Hillmyer MA.
    Mol Pharm; 2019 Oct 07; 16(10):4089-4103. PubMed ID: 31487183
    [Abstract] [Full Text] [Related]

  • 42. Improved Release of Celecoxib from High Drug Loading Amorphous Solid Dispersions Formulated with Polyacrylic Acid and Cellulose Derivatives.
    Xie T, Taylor LS.
    Mol Pharm; 2016 Mar 07; 13(3):873-84. PubMed ID: 26791934
    [Abstract] [Full Text] [Related]

  • 43. Improved Vemurafenib Dissolution and Pharmacokinetics as an Amorphous Solid Dispersion Produced by KinetiSol® Processing.
    Ellenberger DJ, Miller DA, Kucera SU, Williams RO.
    AAPS PharmSciTech; 2018 Jul 07; 19(5):1957-1970. PubMed ID: 29541940
    [Abstract] [Full Text] [Related]

  • 44. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
    Ambrogi V, Perioli L, Marmottini F, Rossi C.
    Eur J Pharm Biopharm; 2007 May 07; 66(2):253-9. PubMed ID: 17123798
    [Abstract] [Full Text] [Related]

  • 45. Polymer/Amorphous Salt Solid Dispersions of Ciprofloxacin.
    Mesallati H, Tajber L.
    Pharm Res; 2017 Nov 07; 34(11):2425-2439. PubMed ID: 28875408
    [Abstract] [Full Text] [Related]

  • 46. An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems.
    Tian Y, Jones DS, Andrews GP.
    Mol Pharm; 2015 Apr 06; 12(4):1180-92. PubMed ID: 25692314
    [Abstract] [Full Text] [Related]

  • 47. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective.
    Gupta P, Kakumanu VK, Bansal AK.
    Pharm Res; 2004 Oct 06; 21(10):1762-9. PubMed ID: 15553220
    [Abstract] [Full Text] [Related]

  • 48. Determinants of zero-order release kinetics from acetaminophen-layered Suglet® pellets, Wurster-coated with plasticized Aquacoat® ECD (ethyl cellulose dispersion).
    Kaur S, Sivasankaran S, Wambolt E, Jonnalagadda S.
    Int J Pharm; 2020 Jan 05; 573():118873. PubMed ID: 31765772
    [Abstract] [Full Text] [Related]

  • 49. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
    Lakshman JP, Cao Y, Kowalski J, Serajuddin AT.
    Mol Pharm; 2008 Jan 05; 5(6):994-1002. PubMed ID: 19434852
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Evaluation of different screening methods to understand the dissolution behaviors of amorphous solid dispersions.
    Lee TW, Boersen NA, Yang G, Hui HW.
    Drug Dev Ind Pharm; 2014 Aug 05; 40(8):1072-83. PubMed ID: 23802148
    [Abstract] [Full Text] [Related]

  • 52. Influence of Glass Forming Ability on the Physical Stability of Supersaturated Amorphous Solid Dispersions.
    Blaabjerg LI, Bulduk B, Lindenberg E, Löbmann K, Rades T, Grohganz H.
    J Pharm Sci; 2019 Aug 05; 108(8):2561-2569. PubMed ID: 30878513
    [Abstract] [Full Text] [Related]

  • 53. Molecular-Level Examination of Amorphous Solid Dispersion Dissolution.
    Faiz Afzal MA, Lehmkemper K, Sobich E, Hughes TF, Giesen DJ, Zhang T, Krauter CM, Winget P, Degenhardt M, Kyeremateng SO, Browning AR, Shelley JC.
    Mol Pharm; 2021 Nov 01; 18(11):3999-4014. PubMed ID: 34570503
    [Abstract] [Full Text] [Related]

  • 54. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions.
    Andrews GP, AbuDiak OA, Jones DS.
    J Pharm Sci; 2010 Mar 01; 99(3):1322-35. PubMed ID: 19798757
    [Abstract] [Full Text] [Related]

  • 55. Liquisolid systems and aspects influencing their research and development.
    Vraníková B, Gajdziok J.
    Acta Pharm; 2013 Dec 01; 63(4):447-65. PubMed ID: 24451071
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions.
    Andrews GP, Abu-Diak O, Kusmanto F, Hornsby P, Hui Z, Jones DS.
    J Pharm Pharmacol; 2010 Nov 01; 62(11):1580-90. PubMed ID: 21072971
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Molecular Factors Governing the Liquid and Glassy States Recrystallization of Celecoxib in Binary Mixtures with Excipients of Different Molecular Weights.
    Grzybowska K, Chmiel K, Knapik-Kowalczuk J, Grzybowski A, Jurkiewicz K, Paluch M.
    Mol Pharm; 2017 Apr 03; 14(4):1154-1168. PubMed ID: 28241116
    [Abstract] [Full Text] [Related]

  • 60. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
    Widanapathirana L, Tale S, Reineke TM.
    Mol Pharm; 2015 Jul 06; 12(7):2537-43. PubMed ID: 26046484
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.